Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.8571.

GANX has been the subject of a number of research reports. Roth Capital lowered their target price on Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Maxim Group raised their price objective on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Finally, BTIG Research restated a “buy” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a report on Wednesday.

Gain Therapeutics Price Performance

GANX stock opened at $1.87 on Friday. The stock has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $1.78. The stock has a market cap of $67.23 million, a PE ratio of -2.97 and a beta of 0.11. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $2.90.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Equities analysts forecast that Gain Therapeutics will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Hedge funds have recently modified their holdings of the stock. Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics in the 1st quarter valued at about $91,000. Dauntless Investment Group LLC bought a new position in shares of Gain Therapeutics in the 1st quarter valued at about $240,000. Marshall Wace LLP grew its holdings in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after acquiring an additional 80,407 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after acquiring an additional 8,251 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.